Neural crest stem cells in melanoma development
O Shakhova - Current opinion in oncology, 2014 - journals.lww.com
O Shakhova
Current opinion in oncology, 2014•journals.lww.comThe development of new therapies, targeting RAF-MEK-ERK pathway, provided major
improvements in outcomes for patients with metastatic melanoma; however, acquired
resistance followed by tumor recurrence represents a major clinical challenge. The striking
parallels between embryonic NCSCs (eNCSCs) and melanoma cells might lead to the
development of new targeted therapeutics selectively eliminating cell populations
accountable for tumor initiation, progression and relapse.
improvements in outcomes for patients with metastatic melanoma; however, acquired
resistance followed by tumor recurrence represents a major clinical challenge. The striking
parallels between embryonic NCSCs (eNCSCs) and melanoma cells might lead to the
development of new targeted therapeutics selectively eliminating cell populations
accountable for tumor initiation, progression and relapse.
Summary
The development of new therapies, targeting RAF-MEK-ERK pathway, provided major improvements in outcomes for patients with metastatic melanoma; however, acquired resistance followed by tumor recurrence represents a major clinical challenge. The striking parallels between embryonic NCSCs (eNCSCs) and melanoma cells might lead to the development of new targeted therapeutics selectively eliminating cell populations accountable for tumor initiation, progression and relapse.
Lippincott Williams & Wilkins